Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia.

[1]  R. D. de Boer,et al.  Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. , 2010, Cardiovascular research.

[2]  R. Garrick.  A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[3]  R. Alcázar,et al.  Cambiará la prescripción de agentes estimulantes de la eritropoyesis en prediálisis tras los resultados del estudio TREAT , 2010 .

[4]  Jiang Tian,et al.  Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. , 2008, American journal of physiology. Renal physiology.

[5]  D. J. Veldhuisen,et al.  Low‐dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit , 2008, European journal of heart failure.

[6]  L. Michalis,et al.  Correction of Anemia with Erythropoietin in Chronic Kidney Disease (stage 3 or 4): Effects on Cardiac Performance , 2008, Cardiovascular Drugs and Therapy.

[7]  G. Takemura,et al.  Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. , 2007, Journal of cardiac failure.

[8]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[9]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[10]  G. Takemura,et al.  Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. , 2006, Cardiovascular research.

[11]  E. Lakatta,et al.  Erythropoietin, Modified to Not Stimulate Red Blood Cell Production, Retains Its Cardioprotective Properties , 2006, Journal of Pharmacology and Experimental Therapeutics.

[12]  G. Takemura,et al.  Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy , 2006, Circulation.

[13]  R. Henning,et al.  Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. , 2005, Journal of the American College of Cardiology.

[14]  P. Ghezzi,et al.  A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Bogoyevitch.  An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. , 2004, Cardiovascular research.

[16]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[17]  G. Wright,et al.  Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia‐reperfusion injury , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  M. Lesch,et al.  Progression of heart failure: A role for interstitial fibrosis , 1995, Molecular and Cellular Biochemistry.

[19]  Richard B. Thompson,et al.  A novel protective effect of erythropoietin in the infarcted heart. , 2003, The Journal of clinical investigation.

[20]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Pietro Ghezzi,et al.  Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Gassmann,et al.  Erythropoietin‐induced excessive erythrocytosis activates the tissue endothelin system in mice , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  Kenneth Maiese,et al.  Erythropoietin Is a Novel Vascular Protectant Through Activation of Akt1 and Mitochondrial Modulation of Cysteine Proteases , 2002, Circulation.

[24]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[25]  K. Amann,et al.  Cardiovascular Changes in Renal Failure , 2002, Blood Purification.

[26]  B. Astor,et al.  Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). , 2002, Archives of internal medicine.

[27]  A. Levin,et al.  Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. , 2002, Kidney international. Supplement.

[28]  G. Eknoyan,et al.  Cardiovascular disease in chronic renal disease. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  I. Rodger,et al.  Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. , 1998, Circulation.

[31]  H. Ochi,et al.  Quantitative immunohistochemical determination of 8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[32]  L. Peng,et al.  Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. , 1997, The Biochemical journal.

[33]  M. Kuhn,et al.  Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. , 1996, Kidney international.

[34]  J. Molkentin,et al.  Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene , 1994, Molecular and cellular biology.

[35]  E. Stadtman,et al.  Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. Nakhoul,et al.  Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. , 1991, The American journal of physiology.

[37]  A. Raine,et al.  Effects of erythropoietin on blood pressure. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  K. Rahn,et al.  Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. , 1991, Kidney international.

[39]  A. Sniderman,et al.  Impact of left ventricular hypertrophy on survival in end-stage renal disease. , 1989, Kidney international.

[40]  M. Fukuda,et al.  Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. , 1989, Blood.